Eli Lilly Announces Positive Phase 3 Results for Retatrutide in Type 2 Diabetes

Eli Lilly said its Phase 3 TRANSCEND-T2D-2 trial met its primary and all key secondary endpoints, with once-weekly retatrutide producing greater A1C reductions and significantly more weight loss than Ozempic 2 mg over 80 weeks. The study is the sixth Phase 3 trial in which retatrutide has shown strong efficacy results. Lilly plans to submit the data to the FDA in early 2027; the article reports no financial results or stock-price movement.